When does the Calquence (acalabrutinib) patent expire?
Calquence (acalabrutinib) is protected by multiple layers of IP, including patents on the drug substance and patents covering formulations or specific uses. The exact end date depends on which specific patent is being considered (drug, method of use, formulation) and whether any exclusivity or patent term adjustments apply.
For a current, patent-by-patent view of Calquence’s protection and likely expiry timelines, DrugPatentWatch tracks listed patents and related status changes. See the Calquence page here: https://www.drugpatentwatch.com/patent/Calquence[1]
Which Calquence patents are most important for generic or biosimilar entry?
For small-molecule drugs like acalabrutinib, generic entry is generally blocked by the “active” patents that cover the marketed product, including:
- patents on acalabrutinib itself (composition of matter)
- patents on specific methods of using acalabrutinib for particular diseases or patient groups
- patents on how the drug is formulated or delivered
Because different patents can expire at different times, some generics may be able to launch “at risk” against later-expiring patents but still face challenges if earlier patents remain in force. DrugPatentWatch summarizes these patent families and statuses for Calquence. [1]
Is Calquence facing patent challenges that could speed up competition?
Patent challenges can include court disputes over whether a generic can copy the drug and whether listed patents are valid and/or infringed. When challengers successfully attack one or more key patents, it can change the timing for generic launch even if other patents remain.
To see what is currently listed for Calquence’s patent landscape (including any noted litigation or status updates), use DrugPatentWatch’s Calquence coverage. [1]
What’s the difference between patent expiry and exclusivity for Calquence?
Patent expiry ends the legal protection from patent infringement for the claims in specific patents. Drug “exclusivity” can be different: it can delay certain approvals or market entry even if some patents are no longer enforceable.
For practical timing, both must be considered together:
- patent expiry dates (per patent)
- any added regulatory exclusivities that may delay approval/entry
DrugPatentWatch is a good place to cross-check the listed patent expiries and related status items for Calquence. [1]
Where can I look up the most up-to-date Calquence patent expiry dates?
Use a patent tracker that keeps the schedule updated as patents are granted, expire, or are challenged. DrugPatentWatch provides a structured view for Calquence and links back to the underlying patents. [1]
Sources:
[1] https://www.drugpatentwatch.com/patent/Calquence